文献速递淋巴瘤

套细胞淋巴瘤中CD163+巨噬细胞诱导促生存通路激活和免疫抑制

CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.
PubMed 文献 · Blood Adv · 2024-01-01

该研究利用空间多组学技术分析100例套细胞淋巴瘤诊断组织的组织微阵列,检测63种蛋白及1811种信使RNA,探索CD163+细胞丰度与空间定位同MCL生物学的关系。发现CD163+细胞依定位调节免疫谱,VISTA和B7-H3在肿瘤稀疏区表达更高,CD163+细胞丰富浸润的MCL组织MAPK通路蛋白和转录表达更高,CD11c和CD163具有独立及联合预后价值。

要点

  • CD163+巨噬细胞丰富浸润的MCL组织MAPK通路关键组分蛋白和转录表达更高。
  • 免疫抑制分子VISTA和B7-H3在肿瘤稀疏区比肿瘤丰富区表达更高。
  • CD11c和CD163具有超越既定危险因素的独立及联合预后价值。

核心结论

  • CD163+细胞依其定位调节免疫谱,MCL组织CD163+细胞丰富浸润者MAPK通路表达更高,MAPK通路可能是伴CD163+细胞浸润MCL患者的可行治疗靶点。
  • CD11c和CD163具有超越既定危险因素的独立及联合预后价值。

研究设计与样本

  • 对100例套细胞淋巴瘤诊断组织的组织微阵列进行空间多组学分析,用GeoMx数字空间分析技术检测63种蛋白。
  • 在肿瘤丰富和肿瘤稀疏组织区域选取感兴趣区,对CD163+巨噬细胞、CD20+ MCL细胞和CD3+ T细胞进行分子谱分析。
  • 在CD20+细胞和2个T细胞亚群中检测1811种信使RNA以验证蛋白谱,并用图像分析提取每个靶向细胞的表型和位置。

主要发现

  • CD163+细胞依其定位调节免疫谱,免疫抑制分子VISTA和B7-H3在肿瘤稀疏区表达高于肿瘤丰富区。
  • CD163+细胞丰富浸润的MCL组织MAPK通路关键组分蛋白和转录表达更高。
  • CD11c和CD163具有超越既定危险因素的独立及联合预后价值。

临床怎么用

  • 针对VISTA和B7-H3的靶向治疗应予以探索。
  • MAPK通路可能是伴CD163+细胞浸润MCL患者的可行治疗靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is dependent on a supportive tumor immune microenvironment (TIME) in which infiltration of CD163+ macrophages has a negative prognostic impact. This study explores how abundance and spatial localization of CD163+ cells are associated with the biology of MCL, using spatial multiomic investigations of tumor and infiltrating CD163+ and CD3+ cells. A total of 63 proteins were measured using GeoMx digital spatial profiling in tissue microarrays from 100 diagnostic MCL tissues. Regions of interest were selected in tumor-rich and tumor-sparse tissue regions. Molecular profiling of CD163+ macrophages, CD20+ MCL cells, and CD3+ T-cells was performed. To validate protein profiles, 1811 messenger RNAs were measured in CD20+ cells and 2 subsets of T cells. Image analysis was used to extract the phenotype and position of each targeted cell, thereby allowing the exploration of cell frequencies and cellular neighborhoods. Proteomic investigations revealed that CD163+ cells modulate their immune profile depending on their localization and that the immune inhibitory molecules, V-domain immunoglobulin suppressor of T-cell activation and B7 homolog 3, have higher expression in tumor-sparse than in tumor-rich tissue regions and that targeting should be explored. We showed that MCL tissues with more abundant infiltration of CD163+ cells have a higher proteomic and transcriptional expression of key components of the MAPK pathway. Thus, the MAPK pathway may be a feasible therapeutic target in patients with MCL with CD163+ cell infiltration. We further showed the independent and combined prognostic values of CD11c and CD163 beyond established risk factors.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. de Matos Rodrigues J, Lokhande L, Olsson LM, et al. CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression. Blood Adv. 2024. PMID: 38959399. doi:10.1182/bloodadvances.2023012039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。